Takahiro Jimbo

Publications (4)6.4 Total impact

• Article: TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.

  Akihiko Yokohama, Akio Saitoh, Hirotaka Nakahashi, Takeki Mitsui, Hiromi Koiso, Yoshitora Kim, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Takahiro Jimbo, Kayoko Murayama, Tohru Sakura, Hirokazu Murakami, Masamitsu Karasawa, Yoshihisa Nojima, Norifumi Tsukamoto
  [show abstract] [hide abstract]
  ABSTRACT: T-cell prolymphocytic leukemia (T-PLL) is a rare type of peripheral T-cell leukemia. In this study, we examined the clinical and biological characteristics of 11 Japanese patients with T-PLL. Median age was 74 years, with male predominance. Median lymphocyte frequency was 85.3% in blood. Physical characteristics were splenomegaly (36.4%), tiny lymph adenopathy (63.6%), skin lesion (9.1%) and pleural effusion (27.3%). Median survival was 30.1 months, despite treatment with various chemotherapeutic modalities. Although complex chromosomal abnormalities were observed in 5 of 11 cases (45.5%), typical 14q32 and Xq28 abnormalities were not detected. TCL1A mRNA expression was observed in 6 of 11 cases (54.5%) on real-time quantitative PCR. In 5 of these 6 cases, flow cytometric analysis and/or immunohistochemistry confirmed the expression of TCLA1 protein. Split signals for the TCL1 region on fluorescence in situ hybridization confirmed rearrangement in 3 out of 7 cases evaluated. These cases corresponded to cases that were positive for TCL1A expression, suggesting that rearrangement of the TCL1 region induced high expression of TCL1A gene. In summary, a substantial number of T-PLL cases in Japan had abnormal expression of TCL1A, probably due to rearrangement of TCL1 region. Expression and/or rearrangement of TCL1A may, therefore, be a useful marker for diagnosing T-PLL, regardless of chromosomal abnormalities.
  International journal of hematology 12/2011; 95(1):77-85. · 1.17 Impact Factor
• Article: Mature natural killer cell lymphoma with an unusual immunophenotype: CD16-, CD56-, and CD57 negative.

  Hiroaki Shimizu, Akihiko Yokohama, Takahiro Jimbo, Takatomo Yoshida, Masaru Kojima, Norifumi Tsukamoto, Yoshihisa Nojima
  European Journal Of Haematology 09/2011; 88(2):181-2. · 2.61 Impact Factor
• Article: Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.

  Hiroaki Shimizu, Takayuki Saitoh, Fumie Ota, Takahiro Jimbo, Yoshito Tsukada, Hirokazu Murakami, Yoshihisa Nojima
  [show abstract] [hide abstract]
  ABSTRACT: Antibody (Ab)-mediated pure red cell aplasia (PRCA) is a rare but important side effect in patients with chronic kidney disease who receive recombinant human erythropoietin (rhEPO). Ab-mediated PRCA was first reported in the 1990s, and the incidence subsequently increased and reached a peak in 2001. After improvements in rhEPO products and the administration route, the incidence was reduced by 90%, and now Ab-mediated PRCA only develops in a limited number of patients who receive rhEPO subcutaneously for a long period. We describe here the clinical course of one such rare patient with Ab-mediated PRCA. The patient was a 70-year-old man with chronic renal failure secondary to diabetic nephropathy. He had not received rhEPO therapy before the initiation of hemodialysis. He started hemodialysis and began to receive rhEPO therapy intravenously. Three months later, his hemoglobin level started declining and he became transfusion dependent. A diagnosis of Ab-mediated PRCA was made by bone marrow examination and detection of anti-EPO Abs. He was successfully treated with cyclosporine and became independent of blood transfusions. This case is a reminder that vigilance is required regarding the development of Ab-mediated PRCA upon rhEPO therapy, regardless of the administration route.
  Acta Haematologica 06/2011; 126(2):114-8. · 1.35 Impact Factor
• Article: Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation.

  Hideki Uchiumi, Takafumi Matsushima, Arito Yamane, Noriko Doki, Hiroyuki Irisawa, Takayuki Saitoh, Tohru Sakura, Takahiro Jimbo, Hiroshi Handa, Norifumi Tsukamoto, Masamitsu Karasawa, Shuichi Miyawaki, Hirokazu Murakami, Yoshihisa Nojima
  [show abstract] [hide abstract]
  ABSTRACT: Disseminated intravascular coagulation (DIC) is one of the important complications to develop in patients with acute myeloid leukemia (AML). While acute promyelocytic leukemia (APL) is a strong risk factor for DIC, other clinical features have not been fully defined. We retrospectively analyzed 161 consecutive adult patients with de novo non-APL AML. DIC was diagnosed in 52 patients (32%); 28 patients at diagnosis and 24 soon after the initiation of induction chemotherapy. Leukocyte counts, C-reactive protein, and lactate dehydrogenase were significantly higher in the DIC+ group. Negative expressions of CD13, CD19, CD34, and HLA-DR were more prevalent in the DIC+ group. On multivariate logistic-regression analysis, variables that were independently associated with the development of DIC were high C-reactive protein, high leukocyte count, negative expressions of CD13 and HLA-DR, and cytogenetics with a normal karyotype or 11q23 abnormality. Although DIC is considered to be associated with serious morbidity and occasional mortality, we did not find any significant differences in the complete remission rate, overall or disease-free survival between DIC+ and DIC- groups. This study is the first to define the clinical characteristics associated with DIC in patients with non-APL AML, but exactly how and when DIC should be treated remains to be determined.
  International Journal of Hematology 09/2007; 86(2):137-42. · 1.27 Impact Factor